RE:RE:RE:Canadian technologyJust to give an idea. We talk about PDCs here and a PDC includes a peptide as the ligand targeting a receptor, but if we would talk in terms of LDC, for ligand as in a ligand drug conjugate, or as in radioligand therapy (RLT), we could add PSMA-617 as a LDC. Here the ligand is not a peptide, it's a small organic molecule. As you can see on the link below with a nice picture of the molecule, the ligand is small, it is attached to the DOTA linker that can chelate Lu177, Ga68 or Ac 225. To clearly understand what is the DOTA linker, look at the second link. So if you can attach the DOTA linker and then the isotope to such a small ligand, I see no reasons why it would not be possible with TH19P01. Understand me well, they need a sound scientific proof of concept before exploring radionuclides, but it should be in their short term plans after they are totally sure SORT1+ concept works.
https://www.researchgate.net/figure/Chemical-structure-of-PSMA-617-68-Ga-and-177-Lu-can-bind-to-PSMA-617_fig5_339828222
https://en.wikipedia.org/wiki/DOTA_%28chelator%29
jfm1330 wrote: The quantity is not a problem. TH1902 has 2 linkers + 2 docetaxel molecules. Ga68, Lu1177 or AC225 Dotatate only has one linker + one isotopes. In theory the loading on TH19P01 is not a problem. The Dota linker is bigger than the succinyl used in TH1902, but the isotopes are smaller. I think theu could do a version of TH19P01 + 1 Dota + 1 isotope. Also, look at clinicaltrials.gov, many ADCs are already in clinical trials using Ac225 because it is seen as a very powerful warhead.
https://clinicaltrials.gov/ct2/results?cond=&term=actinium&cntry=&state=&city=&dist=
Wino115 wrote: Those anecdotal Actinium scans are impressive. I assume you believe they can attach this in enough quantity to the THP1901 PDC? Would be interesting to see if nuclear compounds are part of their plans in the future. So far we know of SN38, siRNA, TKI's. All for the future if this project can get wings soon.
jfm1330 wrote: We had an ignorant here not so long ago complaining about Thera being a Canadian company. This was totally ridiculous. This country, for its size, is as good as any advanced country. A lot of good research is made in Canada. Look at this video from Canadian Nuclear Laboratories, about the production of medical grade Actinium 225. This radioisotope is the next big thing in nuclear therapies against cancers.
Look also at the third link. It is a short presentation by a doctor from Vancouver about the use of actinium 225 instead of Lu177 in eithe neuroendocrine tumors or prostate cancer. Results are simply spectacular. Just imagine if SORT1+ platform concept is fully validated. Imagine future PDCs with actinium 225. This is not science fiction. All parts of these potential PDCs exist now.
I know it cannot happen rapidly, but it shows the incredible potential SORT1+ could have with a much more potent cytotoxic agent than docetaxel. That's why the formal proof of concept is so critical and there is no patent on actinium 225. Thera could develop a new PDC that they would totally own. Also, imagine what it is for a patient like me to see these results. If need be I will go to India to have it, but I hope it could be available in Canada in a few years. The fight against cancer is really progressing fast on many fronts. There is hope.
https://www.youtube.com/watch?v=MjL_LJm8CqI
https://www.cnl.ca/health-science-2/actinium-225/
https://www.youtube.com/watch?v=A3tpUKgf7gQ